Onyx Rejects $10 Billion Takeover Bid From Amgen

Updated with new information.

South San Francisco, Calif. ( TheStreet) -- Onyx Pharmaceuticals ( ONXX) confirmed receipt of a takeover offer from Amgen ( AMGN) valued at $120 per share but said the bid was too low. Onyx will now seek competitive bids from other interested acquirers, the company said Sunday.

The Financial Post first broke the story Friday night of Amgen's interest in Onyx, citing an unsolicited bid letter.

"I feel a timely combination of our organizations would be very complementary," said the letter written by Amgen to Onyx two weeks ago, according to the Financial Post story. The letter goes on to propose an Amgen acquisition of Onyx for $120 per share, or $10 billion in total.

Onyx shares jumped 19% to $107.50 in Friday after-market trading on news of the Amgen bid.

On Sunday, Onyx said the Amgen offer "significantly undervalued" the company and was not in the best interests of shareholders.

"Based upon expressions of interest received from other third parties and the recent proposal from Amgen, the Onyx Board has authorized its financial advisor to contact potential acquirers who may have an interest in the Company in a transaction that is in the best interest of Onyx shareholders," the company stated.

Amgen shares were unchanged at $96.88 in after-hours trading.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

FDA Approves First 'Biosimilar' for Cancer Treatment

Amgen Builds on a Breakout

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback